Abstract: Provided are various embodiments relating to feline erythropoietin (EPO) polypeptide analogs with one or more additional glycosylation sites and methods of producing and using the same to treat anemia in companion animals. Also provided are various embodiments relating to EPO polypeptides having a mutation in the second binding site, polypeptides comprising an extracellular domain of EPO receptor, and methods of using the same for treating polycythemia in mammals.

Abstract: An antenna transmission device includes a shell, an output unit, and an input unit. The output unit is slidingly arranged at the shell and includes a rack. The input unit is at least partially arranged in the shell, meshes with the rack of the output unit, and is configured to drive the output unit to move linearly.

Abstract: Provided are various embodiments relating to feline erythropoietin (EPO) polypeptide analogs with one or more additional glycosylation sites and methods of producing and using the same to treat anemia in companion animals. Also provided are various embodiments relating to EPO polypeptides having a mutation in the second binding site, polypeptides comprising an extracellular domain of EPO receptor, and methods of using the same for treating polycythemia in mammals.

Abstract: A phase shifter transmission device includes: a power mechanism, a driving rod, a plurality of transmission assemblies, and at least one row of phase shifters. The power mechanism is connected to the driving rod and configured to drive the driving rod to rotate. The plurality of transmission assemblies are connected to the driving rod, distributed along an axial direction of the driving rod, and driven by the driving rod to rotate synchronously. Each row of phase shifters includes a plurality of phase shifters distributed along the axial direction of the driving rod, and each phase shifter of each row of phase shifters is connected to the corresponding transmission assembly. The at least one row of phase shifters are configured, when being driven by the plurality of transmission assemblies, to synchronously adjust phases of radiated signals corresponding to the phase shifters.

Abstract: An antenna transmission device includes a shell, an output unit, and an input unit. The output unit is slidingly arranged at the shell and includes a rack. The input unit is at least partially arranged in the shell, meshes with the rack of the output unit, and is configured to drive the output unit to move linearly.

Abstract: An antenna transmission device includes a shell, an output unit, and an input unit. The output unit is slidingly arranged at the shell and includes a rack. The input unit is at least partially arranged in the shell, meshes with the rack of the output unit, and is configured to drive the output unit to move linearly.

Abstract: An antenna transmission device includes a shell, an output unit, and an input unit. The output unit is slidingly arranged at the shell and includes a rack. The input unit is at least partially arranged in the shell, meshes with the rack of the output unit, and is configured to drive the output unit to move linearly.

Abstract: Disclosed by the present invention is a transmission device for an antenna phase shifter, comprising a transmission input portion, a shift selection portion, and a transmission output portion; the transmission input portion is fully separated from the shift selection portion, by means of the shift selection portion, the transmission input portion establishes transmission connection with any output terminal of the transmission output portion, thereby performing phase adjustment on a phase shifter that is connected to the output terminal. In the present invention, two motors are responsible for power input and selection output respectively so as to select to drive any number of phase shifters; furthermore, the structure is compact, and output terminals of the transmission output portions may be spread out flat, being beneficial for antenna layout.

Abstract: An antenna element includes a base body. The base body includes a plate portion, a support column, and a metal layer. The plate portion is formed by non-metallic material. The at least one support column, each of the support column is connected to the plate portion. The metal layer covers the base body.

Abstract: Provided are various embodiments relating to variant IgG Fc polypeptides of companion animals having increased Protein A binding for ease of purification, decreased C1q binding for reduced complement-mediated immune responses, decreased CD 16 binding (e.g., for reduced antibody-dependent cellular cytotoxicity (ADCC) induction), increased stability, and/or the ability to form multimeric proteins. In addition, various embodiments relating to antibodies and fusion proteins comprising such variant IgG Fc polypeptides are provided. In various embodiments, such polypeptides may be used to treat companion animals, such as canines, felines, and equines.

Abstract: A phase shifter transmission device includes: a power mechanism, a driving rod, a plurality of transmission assemblies, and at least one row of phase shifters. The power mechanism is connected to the driving rod and configured to drive the driving rod to rotate. The plurality of transmission assemblies are connected to the driving rod, distributed along an axial direction of the driving rod, and driven by the driving rod to rotate synchronously. Each row of phase shifters includes a plurality of phase shifters distributed along the axial direction of the driving rod, and each phase shifter of each row of phase shifters is connected to the corresponding transmission assembly. The at least one row of phase shifters are configured, when being driven by the plurality of transmission assemblies, to synchronously adjust phases of radiated signals corresponding to the phase shifters.

Abstract: A phase shifter assembly includes: a first phase shifter including a first through-hole; a second phase shifter including a second through-hole and disposed at a side of the first phase shifter; a first gear including a third through-hole and disposed at a side of the second phase shifter facing away from the first phase shifter; a rack configured to drive, through driving the first gear, the second phase shifter to move relative to the first phase shifter, to adjust an electrical tilt angle of an antenna corresponding to the phase shifter assembly; and a first reversing mechanism disposed between the first gear and the rack and engaged with the first gear and the rack, respectively, making a direction of a component of a linear velocity at an electrical contact between the first phase shifter and the second phase shifter in a moving direction of the rack is opposite to the moving direction of the rack.

Abstract: Provided are various embodiments relating to feline erythropoietin (EPO) polypeptide analogs with one or more additional glycosylation sites and methods of producing and using the same to treat anemia in companion animals. Also provided are various embodiments relating to EPO polypeptides having a mutation in the second binding site, polypeptides comprising an extracellular domain of EPO receptor, and methods of using the same for treating polycythemia in mammals.

Abstract: Provided are various embodiments relating to variant IgG Fc polypeptides of companion animals having increased Protein A binding for ease of purification, decreased C1q binding for reduced complement-mediated immune responses, decreased CD16 binding (e.g., for reduced antibody-dependent cellular cytotoxicity (ADCC) induction, increased stability, and/or the ability to form heterodimeric proteins. In addition, various embodiments relating to antibodies and fusion proteins comprising such variant IgG Fc polypeptides are provided. Also provided are various embodiments relating to contiguous polypeptides comprising one or more variant GLP1 polypeptide(s) having improved serum half-life. Further provided are various embodiments relating to contiguous polypeptides or heterodimeric polypeptides comprising a GLP1 polypeptide and a glucagon polypeptide as a dual GLP1 receptor and glucagon receptor agonist.

Abstract: Disclosed by the present invention is a transmission device for an antenna phase shifter, comprising a transmission input portion, a shift selection portion, and a transmission output portion; the transmission input portion is fully separated from the shift selection portion, by means of the shift selection portion, the transmission input portion establishes transmission connection with any output terminal of the transmission output portion, thereby performing phase adjustment on a phase shifter that is connected to the output terminal. In the present invention, two motors are responsible for power input and selection output respectively so as to select to drive any number of phase shifters; furthermore, the structure is compact, and output terminals of the transmission output portions may be spread out flat, being beneficial for antenna layout.

Abstract: A small base station antenna is disclosed, said small base station antenna having a length less than 0.4 m, and comprising a carriage, an antenna core assembly and an antenna shell, said small base station antenna capable of being mounted to a holding pole at one point through a mounting rack, characterized in that said small base station antenna further comprises a shock absorption part disposed between the carriage and the antenna shell so as to reduce the vibration frequency transmitted into the antenna core assembly. A method for reducing vibration frequency transmission in a small base station antenna is further disclosed. The present invention addresses the issue that a small base station antenna operates normally under high frequency vibration, such that the small base station antenna can pass the sinusoidal vibration test and random vibration test required by the industry, and can even pass the stricter impact test.

Abstract: A Chinese medicinal composition useful in preventing and treating cancer comprises a composition of either Group A or Group B. Group A comprises: 5-90.5% powder of head of soft-shelled turtle; 0.5-5% powder of musk; 2-20% powder of bear gall; 5-60% powder of ageratum; and 2-10% powder of rhubarb. Group B comprises: 5-90.5% of tail of soft-shelled turtle; 5-60% of powder of Sichuan fritillary bulb; 2-20% of powder of bear gall; 2-10% powder of rhubarb; and 0.5-5% of powder of musk. The Group A and Group B compositions are taken alternatively by the patient each time. The ingredients used in this invention may be easily obtained, have a low cost, and a notable effect.

Abstract: This invention opens a prescription of a pure biological life-prolong product. The product is made from the following ingredients in weight proportion: soft-shelled turtle 100, ageratum 2-5, ginseng 2-5, and glucose 2-5. Every ingredient is ground into powder and mixed together in proportion; then add an appropriate amount of water, boil by slow fire and filtrate into aqua form, or dry the filtrate and extract into powder form, bolus form or tablet form. This medicine can improve human immune functions, accelerate human metabolism by the increase of cell division and cell regeneration so as to reach the goal of cancer prevention and treatment, youth keeping and life prolong.

Abstract: A Chinese medicinal composition useful in preventing and treating cancer comprises: